Teva does comparatively well under ObamaCare because Copaxone has little exposure to Medicaid. Moreover, the new regulatory pathway for biogenerics/biosimilars should help Teva in due course.
Teva's CFO Eyal Desheh said at the Oppenheimer annual conference in Tel Aviv, that the healthcare reform will reduce Teva's revenue by $80-100M a year.
Market Data 
Markets 
AI
